Abstract Purpose: Altered PI3K/mTOR signaling is implicated in the pathogenesis of a
number of breast cancers, including those resistant to hormonal and HER2-targeted …

Human epidermal growth factor receptor 2–positive (HER2+) breast cancers, which account
for 25%-30% of breast cancers, are characterized by an aggressive course and a high …

Abstract Purpose: The PI3K/Akt/mTOR pathway is an attractive target in HER2-positive
breast cancer that is refractory to anti-HER2 therapy. The hypothesis is that the suppression …

The activation of the PI3K signaling pathway resulting from genetic alterations induces
carcinogenesis and resistance to anticancer therapies. Breast cancer is a major malignancy …

Breast cancer is one of the most prevalent and devastating malignant diseases in women
worldwide. Fortunately, while breast cancer incidence is still increasing, its death rate is …

Anti-cancer cancer-targeted therapies are designed to exploit a particular vulnerability in the
tumor, which in most cases results from its dependence on an oncogene and/or loss of a …

Abstract Approximately 70− 75% of breast cancers express the estrogen receptor (ER),
indicating a level of dependence on estrogen for growth. Endocrine therapy is an important …

Activation of the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway is common in
breast cancer. PI3K pathway activation has been associated with tumor growth and …

Increased activation of the PI3K/Akt/mTOR pathway is a common factor in putative
mechanisms of trastuzumab resistance, resulting in dysregulation of cell migration, growth …

There is a strong rationale to therapeutically target the phosphatidylinositol 3-kinase/protein
kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway in breast cancer since …